Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase and Type 2 diabetes?: the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit

M Yadagiri¹, P Sen Gupta¹, SC Bain², A Robinson³, K Darzy⁴, A Kennedy⁵, KA Adamson⁶, REJ Ryder¹

¹Sandwell and West Birmingham Hospitals NHS Trust, Birmingham

²Abertawe Bro Morgannwg University NHS Trust, Swansea/Neath

HbA1c, weight, body mass index (BMI) and systolic blood pressure changes in the ABCD nationwide dapagliflozin audit

M Yadagiri¹, P Sen Gupta¹, ML Cull¹, R Peter², P De¹, A Robinson³, KA Adamson⁴, REJ Ryder¹ on behalf of the ABCD nationwide dapagliflozin audit contributors

¹Sandwell and West Birmingham Hospitals NHS Trust, Birmingham

²Abertawe Bro Morgannwg University NHS Trust, Swansea/Neath

Dapagliflozin in renal impairment: Association of British Clinical Diabetologists (ABCD) Nationwide Dapagliflozin Audit

M Yadagiri, S Bain, T Robinson, JP Wilding, T Pang, B Mcgowan, P Winocour, V Oguntolu, J Clarke, H Partridge, IW Gallen, K Adamson, REJ Ryder On behalf of the ABCD nationwide dapagliflozin audit contributors

Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase (ALT) and Type 2 diabetes? Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit

Mahender Yadagiri ABCD Research Fellow P Sen Gupta, JW Stephens, A Robinson, M Phylactou, A Kennedy, J Clarke , J Wilding, IW Gallen, K A Adamson, R E J Ryder On behalf of the ABCD nationwide dapagliflozin audit contributors

HbA1c, weight, body mass index (BMI) and systolic blood pressure changes in the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit 

Mahender Yadagiri ABCD Research Fellow ST5 Diab & Endo P Sen Gupta, M L Cull, R Peter, P De, A Robinson, KA Adamson, REJ Ryder on behalf of the ABCD nationwide dapagliflozin audit contributors

Clinical risk factors predicting genital fungal infections with sodium–glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit

Two year metabolic outcomes in the Association of British Clinical Diabetologist (ABCD) Nationwide Canagliflozin Audit: a comparison of glycaemic improvements

Dr A Puttanna^*1, Dr M Yadagiri¹, Dr P Sen Gupta¹, Dr IW Gallen², Dr A Bickerton³, Dr S Phillips⁴, Dr A Evans⁴, Dr D Sennik⁵, Dr REJ Ryder¹, ABCD nationwide canagliflozin audit contributors⁶

¹Diabetes and Endocrinology, Sandwell and West Birmingham NHS Trust, Birmingham, UK

2 year metabolic outcomes in the ABCD nationwide canagliflozin audit Author Block:

A. Puttanna¹, M. Yadagiri¹, P. Sen Gupta¹, I. Gallen², A. Bickerton³, S. Phillips⁴, A. Evans⁴, D. Sennik⁵, R. Ryder¹

¹Diabetes and Endocrinology, Sandwell and West Birmingham NHS Trust, Birmingham, UK

²Diabetes and Endocrinology, Royal Berkshire Hospitals NHS Trust, Berkshire, UK

Relationship Between Canagliflozin Treatment Response and Duration of Diabetes: The Association of British Clinical Diabetologists (ABCD) Nationwide Canagliflozin Audit

Two year metabolic outcomes in the Association of British Clinical Diabetologist (ABCD) Nationwide Canagliflozin Audit: a comparison of glycaemic improvements

A Puttanna¹, M Yadagiri¹, P Sen Gupta¹, I W Gallen², A Bickerton³, S Phillips⁴, A Evans⁴ , D Sennik⁵, R E J Ryder¹ and ABCD nationwide canagliflozin audit contributors⁶